CYP24A1

Summary

CYP24A1 (cytochrome P450 family 24 subfamily A member 1, HGNC:2602) is a protein-coding gene on chromosome 20q13.2, encoding 1,25-dihydroxyvitamin D(3) 24-hydroxylase, mitochondrial (Q07973). A cytochrome P450 monooxygenase with a key role in vitamin D catabolism and calcium homeostasis.

This gene encodes a member of the cytochrome P450 superfamily of enzymes. The cytochrome P450 proteins are monooxygenases which catalyze many reactions involved in drug metabolism and synthesis of cholesterol, steroids and other lipids. This mitochondrial protein initiates the degradation of 1,25-dihydroxyvitamin D3, the physiologically active form of vitamin D3, by hydroxylation of the side chain. In regulating the level of vitamin D3, this enzyme plays a role in calcium homeostasis and the vitamin D endocrine system. Alternatively spliced transcript variants encoding different isoforms have been found for this gene.

Source: NCBI Gene 1591 — RefSeq curated summary.

At a glance

• Gene–disease (curated): hypercalcemia, infantile, 1 (Strong, GenCC) — +1 more curated relationship
• GWAS associations: 27
• Clinical variants (ClinVar): 460 total — 31 pathogenic, 23 likely-pathogenic
• Phenotypes (HPO): 15
• Druggable target: yes — 4 molecules with ChEMBL bioactivity
• Dosage sensitivity (ClinGen): haploinsufficiency autosomal recessive, triplosensitivity unscored
• MANE Select transcript: NM_000782

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:2602
Approved symbol	CYP24A1
Name	cytochrome P450 family 24 subfamily A member 1
Location	20q13.2
Locus type	gene with protein product
Status	Approved
Aliases	CP24, P450-CC24, lncBCAS1-4_1
Ensembl gene	ENSG00000019186
Ensembl biotype	protein_coding
OMIM	126065
Entrez	1591

Gene structure

Transcript identifiers

Ensembl transcripts: 9 — 6 protein_coding, 3 protein_coding_CDS_not_defined

ENST00000216862, ENST00000395954, ENST00000395955, ENST00000460643, ENST00000472970, ENST00000487593, ENST00000869535, ENST00000869536, ENST00000869537

RefSeq mRNA: 6 — MANE Select: NM_000782 NM_000782, NM_001128915, NM_001424340, NM_001424341, NM_001424342, NM_001424343

CCDS: CCDS33491, CCDS46616

Canonical transcript exons

ENST00000216862 — 12 exons

Exon	Start	End
ENSE00000662846	54157388	54157585
ENSE00000662847	54158086	54158164
ENSE00000662848	54158957	54159123
ENSE00000662849	54162717	54162862
ENSE00000662850	54164452	54164563
ENSE00000662851	54165742	54165833
ENSE00000662852	54169592	54169688
ENSE00000662853	54171577	54171670
ENSE00000662854	54172909	54173099
ENSE00000845669	54153446	54154761
ENSE00000845670	54157169	54157289
ENSE00000845671	54173322	54173986

Expression profiles

Bgee: expression breadth ubiquitous, 163 present calls, max score 91.53.

FANTOM5 (CAGE): breadth broad, TPM avg 4.6652 / max 635.0835, expressed in 331 samples.

FANTOM5 promoters (4 alternative TSS)

Promoter ID	TPM avg	Samples expressed
188072	4.5316	321
188071	0.0554	23
188069	0.0415	15
188073	0.0367	14

Top tissues by expression

273 total, by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
olfactory segment of nasal mucosa	UBERON:0005386	91.53	gold quality
secondary oocyte	CL:0000655	87.96	gold quality
male germ line stem cell (sensu Vertebrata) in testis	CL:0000089 ∩ UBERON:0000473	83.34	gold quality
mucosa of urinary bladder	UBERON:0001259	80.24	gold quality
oocyte	CL:0000023	79.31	gold quality
adult mammalian kidney	UBERON:0000082	78.91	gold quality
epithelium of nasopharynx	UBERON:0001951	77.44	silver quality
primordial germ cell in gonad	CL:0000670 ∩ UBERON:0000991	75.36	gold quality
urinary bladder	UBERON:0001255	74.68	gold quality
metanephros cortex	UBERON:0010533	74.23	gold quality
lower esophagus mucosa	UBERON:0035834	73.85	gold quality
gingival epithelium	UBERON:0001949	71.96	silver quality
kidney	UBERON:0002113	71.88	gold quality
nasal cavity mucosa	UBERON:0001826	71.74	gold quality
esophagus mucosa	UBERON:0002469	69.83	gold quality
gingiva	UBERON:0001828	68.56	silver quality
palpebral conjunctiva	UBERON:0001812	66.99	silver quality
cortex of kidney	UBERON:0001225	66.78	gold quality
tonsil	UBERON:0002372	65.96	gold quality
nephron tubule	UBERON:0001231	65.85	silver quality
endocervix	UBERON:0000458	64.80	gold quality
metanephros	UBERON:0000081	64.38	gold quality
seminal vesicle	UBERON:0000998	64.09	gold quality
bronchial epithelial cell	CL:0002328	63.22	silver quality
metanephric glomerulus	UBERON:0004736	62.81	silver quality
epithelium of bronchus	UBERON:0002031	61.52	silver quality
bronchus	UBERON:0002185	61.24	silver quality
mucosa of paranasal sinus	UBERON:0005030	61.12	silver quality
placenta	UBERON:0001987	60.97	gold quality
prefrontal cortex	UBERON:0000451	60.54	gold quality

Single-cell (SCXA)

Detected in 1 experiment(s), a significant marker in 1.

Experiment	Marker?	Max mean expression
E-ANND-3	yes	7.27

Regulation

Is transcription factor: no

Upstream regulators (CollecTRI, top): CTNNB1, ETS1, ETV7, HR, KAT7, NCOR2, NR1I2, NR1I3, NR2C2, RXRA, SNAI2, TBP, TP53, VDR

miRNA regulators (miRDB)

81 targeting CYP24A1, top 30 by miRDB confidence (max_score; target_count = how many genes the miRNA targets in total — lower means more specific):

miRNA	Max score	Avg score	miRNA target_count
HSA-MIR-30A-5P	100.00	76.31	3233
HSA-MIR-30B-5P	100.00	76.29	3248
HSA-MIR-30C-5P	100.00	76.29	3248
HSA-MIR-30D-5P	100.00	76.32	3233
HSA-MIR-30E-5P	100.00	76.32	3242
HSA-MIR-8485	100.00	77.57	4731
HSA-MIR-5692A	100.00	74.40	6850
HSA-MIR-5692B	100.00	71.32	2622
HSA-MIR-5692C	100.00	71.32	2622
HSA-MIR-340-5P	100.00	72.50	4437
HSA-MIR-548C-3P	99.99	74.01	7587
HSA-MIR-548AJ-3P	99.96	73.38	5345
HSA-MIR-548X-3P	99.96	73.38	5345
HSA-MIR-493-5P	99.96	72.47	2382
HSA-MIR-551B-5P	99.96	71.28	3493
HSA-MIR-23A-3P	99.95	74.24	3163
HSA-MIR-23B-3P	99.95	74.24	3163
HSA-MIR-23C	99.95	73.92	3192
HSA-MIR-548J-3P	99.94	72.61	4881
HSA-MIR-144-3P	99.94	73.98	2698
HSA-MIR-548AE-3P	99.93	72.66	4867
HSA-MIR-548AH-3P	99.93	72.54	4872
HSA-MIR-548AM-3P	99.93	72.54	4872
HSA-MIR-548AQ-3P	99.93	72.66	4867
HSA-MIR-338-5P	99.92	72.34	2951
HSA-MIR-6768-5P	99.92	67.36	1942
HSA-MIR-498-3P	99.91	71.27	1114
HSA-MIR-374A-5P	99.90	71.34	2923
HSA-MIR-374B-5P	99.90	69.98	2734
HSA-MIR-345-3P	99.89	70.23	1421

Functional genomics

ClinGen dosage: haploinsufficiency 30 (autosomal recessive), triplosensitivity Not yet evaluated (unscored). ClinGen Gene Dosage Map

Literature-anchored findings (GeneRIF, showing 40)

• Transcription is inhibited by genistein. (PMID:12485911)
• results suggest that 1,25-dihydroxyvitamin D3 rapid effects require the presence of vitamin D receptor and control, in part, the vitamin D catabolism via increased expression of the 24-hydroxylase and ferredoxin genes (PMID:14665637)
• Overexpression of the candidate oncogene CYP24 is inversely correlated to vitamin D receptor expression, and may play an important role in determination of the malignant potential of esophageal cancer (PMID:14760115)
• In this paper, novel metabolites of 1 alpha,25-dihydroxyvitamin D3 and 25(OH)D3 catalyzed by human enzyme CYP24A1 are presented. These metabolites appear to be closely related to the C-23 hydroxylation pathway. (PMID:15078099)
• Metabolism of A-ring diastereomers of calcitriol was examined to compare the substrate specificity and reaction specificity of CYP24A1 between humans and rats. (PMID:15358094)
• xenobiotics and drugs can modulate CYP24 gene expression and alter vitamin D(3) hormonal activity and calcium homeostasis through the activation of pregnane X receptor (PMID:15630458)
• data suggest that alternative splicing of vitamin D-24-hydroxylase (CYP24) leads to the generation of a dominant negative-acting protein that is catalytically dysfunctional and may contribute to the extracellular accumulation of 1,25-dihydroxyvitamin D (PMID:15788398)
• information concerning the regulation of the CYP24 gene by 1alpha,25OH2D3, and is a demonstration of the simultaneous participation of multiple, structurally diverse response elements in promoter activation in a living cell (PMID:15919092)
• Real-time RT-PCR showed that exposure of HL-60 cells to 1,25(OH)(2)D(3) induced expression of CYP24. (PMID:16457885)
• CYP24A1 can activate and inactivate vitamin D prodrugs in skin and other target cells in vitro (PMID:16516540)
• Haplotype association were found only for CYP24A1, the main calcidiol degrading enzyme in the vitamin D turnover or signalling pathway. (PMID:16600026)
• CYP24A1 mutant I500F showed quite a different metabolism of 1alpha,25-dihydroxyvitamin D3. (PMID:16617161)
• Data show that activation of steroid and xenobiotic receptor does not induce cytochrome P450, family 24 (CYP24)-mediated expression, but inhibits vitamin D receptor-mediated CYP24 promoter activity. (PMID:16691293)
• increased CYP24 expression in lung tumors restricts 1,25D3 activity and support the preclinical evaluation of CYP24 inhibitors for lung cancer treatment (PMID:16708384)
• The overall data suggest that calcitriol downregulates CYP27B1 expression via a cAMP-dependent signaling pathway, whereas upregulates 24-hydroxylase gene expression through a VDR-dependent mechanism. (PMID:17079137)
• CYP27B1 gene could play a functional role in the pathogenesis of type 1 diabetes through modulation of its mRNA expression and influence serum levels of 1,25(OH)(2)D(3) via the -1260 C/A polymorphism (PMID:17223345)
• local 1,25D synthesis has paracrine effects in the bone microenvironment implying that vitamin D metabolism in human osteoblasts represents a physiologically important pathway (PMID:17254772)
• differences in CYP24 splicing are associated with different patterns of CYP24 activity (PMID:17368180)
• Upstream sequence and the 5’-untranslated region of CYP24 did not appear to play a major role in the vitamin D response. (PMID:17475215)
• In conclusion, CAR/PXR and VDR bind to and transactivate the same response elements in CYP24 promoter. (PMID:17585873)
• Ala-326 is located in the I-helix, close to the terminus of the docked 25-hydroxylated side chain in a CYP24A1 homology model (PMID:17646648)
• CYP27A1 and CYP24 expression is a function of malignant transformation in the colon (PMID:17875655)
• Genotypes of CYP27B1 and CYP24A1 were not associated with prostate cancer risk. (PMID:17932346)
• It inactivate vitamin D and its expression is controlled by mechanical stress and mitogen activated protein kinase. (PMID:18467787)
• VDRE2 variant results in decreased protein binding and transactivation in vitro, and reduced expression of CYP24A1 in cultured primary human lymphocytes (PMID:18824104)
• Data show that there are both promoter-specific and cell stage-specific roles for the ERK1/2 signaling pathway on 1,25(OH)(2)D(3)-mediated CYP24 gene induction in enterocyte-like Caco-2 cells. (PMID:19097033)
• CYP24A1 gene is methylated in human placenta, purified cytotrophoblasts, and primary and cultured chorionic villus sampling tissue. (PMID:19237542)
• Single nucleotide polymorphisms may be associated with risk of prostate cancer in men with low vitamin D status. (PMID:19255064)
• These results indicate that human CYP24A1 catalyzes the C24-C25 bond cleavage of 1alpha,24,25(OH)2D2, which is quite effective in the inactivation of the active form of vitamin D2. (PMID:19393625)
• common genotypic variation found in VDR, CYP27B1, and CYP24A1 has little or no effect on overall prostate cancer risk (PMID:19454612)
• Alternative splicing of 24-OHase may lead to a catalytically dysfunctional enzyme and may lead to less reduction of the target protein (PMID:19667160)
• The CYP24A1 polymorphism IVS4-66T > G showed a statistically significant association with risk of colon cancer overall, particularly for proximal colon cancer. (PMID:19706847)
• This is the first study to correlate CYP24A1 protein levels with proliferation, suggesting that CYP24A1 overexpression counteracts the antiproliferative effect of 1,25-D3 during tumor progression. (PMID:19901270)
• 1,25-dihydroxyvitamin D3 can activate PKC zeta and that the PI3-kinase-PKC zeta cascade regulates the CYP24 promoter. (PMID:19922790)
• analysis of expression of serum vitamin D receptor, cyclooxygenase-2, and 15-hydroxyprostaglandin dehydrogenase in benign and malignant ovarian tissue and 25-hydroxycholecalciferol and prostaglandin E2 in ovarian cancer patients (PMID:20304053)
• human PBLs show only weak methylation in the upstream region of CYP27B1 and none in CYP24A1 (PMID:20304056)
• epigenetic silencing of CYP24 modulates cellular responses to calcitriol (PMID:20304059)
• analysis of CYP24A1 splicing variants in human colon cancer cell lines and tissue samples (PMID:20398751)
• 1,25D-mediated induction of human CYP24A1 is dependant upon a promoter region spanning nucleotides -470 to -392 of the human CYP24A1 promoter. (PMID:20450955)
• the number of vitamin D receptor binding sites defines the different vitamin D responsiveness of the CYP24 gene in malignant and normal mammary cells (PMID:20460683)

Cross-species orthologs

4 orthologs

Organism	Symbol	Gene ID
danio_rerio	cyp24a1	ENSDARG00000103277
mus_musculus	Cyp24a1	ENSMUSG00000038567
rattus_norvegicus	Cyp24a1	ENSRNOG00000013062
drosophila_melanogaster	sad	FBGN0003312

Paralogs (3): CYP27B1 (ENSG00000111012), CYP27A1 (ENSG00000135929), CYP27C1 (ENSG00000186684)

Protein

Protein identifiers

1,25-dihydroxyvitamin D(3) 24-hydroxylase, mitochondrial — Q07973 (reviewed: Q07973)

Alternative names: Cytochrome P450 24A1, Cytochrome P450-CC24

All UniProt accessions (1): Q07973

UniProt curated annotations — full annotation on UniProt →

Function. A cytochrome P450 monooxygenase with a key role in vitamin D catabolism and calcium homeostasis. Via C24- and C23-oxidation pathways, catalyzes the inactivation of both the vitamin D precursor calcidiol (25-hydroxyvitamin D(3)) and the active hormone calcitriol (1-alpha,25-dihydroxyvitamin D(3)). With initial hydroxylation at C-24 (via C24-oxidation pathway), performs a sequential 6-step oxidation of calcitriol leading to the formation of the biliary metabolite calcitroic acid. With initial hydroxylation at C-23 (via C23-oxidation pathway), catalyzes sequential oxidation of calcidiol leading to the formation of 25(OH)D3-26,23-lactone as end product. Preferentially hydroxylates at C-25 other vitamin D active metabolites, such as CYP11A1-derived secosteroids 20S-hydroxycholecalciferol and 20S,23-dihydroxycholecalciferol. Mechanistically, uses molecular oxygen inserting one oxygen atom into a substrate, and reducing the second into a water molecule, with two electrons provided by NADPH via FDXR/adrenodoxin reductase and FDX1/adrenodoxin.

Subcellular location. Mitochondrion.

Disease relevance. Hypercalcemia, infantile, 1 (HCINF1) [MIM:143880] A disorder characterized by abnormally high level of calcium in the blood, failure to thrive, vomiting, dehydration, and nephrocalcinosis. The disease is caused by variants affecting the gene represented in this entry.

Miscellaneous. Specifically expressed in macrophages. Lacks the transit peptide. May be a dominant negative-acting isoform possibly by sequestering vitamin D metabolites.

Similarity. Belongs to the cytochrome P450 family.

Isoforms (3)

UniProt ID	Names	Canonical?
Q07973-1	1	yes
Q07973-2	2
Q07973-3	3, CYP24-SV

RefSeq proteins (6): NP_000773, NP_001122387, NP_001411269, NP_001411270, NP_001411271, NP_001411272 (=MANE)

Domains & families (InterPro)

ID	Name	Type
IPR001128	Cyt_P450	Family
IPR002401	Cyt_P450_E_grp-I	Family
IPR017972	Cyt_P450_CS	Conserved_site
IPR036396	Cyt_P450_sf	Homologous_superfamily
IPR050479	CYP11_CYP27_families	Family

Pfam: PF00067

Enzyme classification (BRENDA):

• EC 1.14.14.24 — vitamin D 25-hydroxylase (BRENDA: 7 organisms, 34 substrates, 4 inhibitors, 22 Km, 14 kcat entries)
• EC 1.14.15.16 — vitamin D3 24-hydroxylase (BRENDA: 3 organisms, 62 substrates, 46 inhibitors, 21 Km, 13 kcat entries)

Substrate kinetics (BRENDA)

15 substrates with measured Km, best-characterized 15. Km ranges are aggregated across organisms/conditions.

Substrate	Km (mM)	Measurements
1ALPHA,25-DIHYDROXYVITAMIN D3	0.0001–0.0011	11
1ALPHA-HYDROXYVITAMIN D3	0.0006–0.0113	6
VITAMIN D3	0.0008–0.032	6
1ALPHA-HYDROXYVITAMIN D2	0.0042–0.018	4
BUFURALOL	0.001–0.0014	2
VITAMIN D2	0.0004–0.002	2
25-HYDROXYVITAMIN D3	0.0002–0.0003	2
CALCITRIOL	0.0086–0.009	2
1ALPHA-HYDROXYCHOLECALCIFEROL	0.054	1
25-HYDROXY-VITAMIN D3	0.0071	1
1ALPHA,25-DIHYDROXY-3-EPI-VITAMIN D3	0.0001	1
1BETA,25-DIHYDROXY-3-EPI-VITAMIN D3	0.0012	1
1BETA,25-DIHYDROXYVITAMIN D3	0.0001	1
2-METHYLENE-19-NOR-(20R)-1,25-DIHYDROXYVITAMIN D	0.0003	1
2-METHYLENE-19-NOR-(20S)-1,25-DIHYDROXYVITAMIN D	0.0001	1

Catalyzed reactions (Rhea), 12 shown:

• calcitriol + 2 reduced [adrenodoxin] + O2 + 2 H(+) = calcitetrol + 2 oxidized [adrenodoxin] + H2O (RHEA:24964)
• calcidiol + 2 reduced [adrenodoxin] + O2 + 2 H(+) = secalciferol + 2 oxidized [adrenodoxin] + H2O (RHEA:24968)
• calcitetrol + 2 reduced [adrenodoxin] + O2 + 2 H(+) = (1S)-1,25-dihydroxy-24-oxocalciol + 2 oxidized [adrenodoxin] + 2 H2O (RHEA:24972)
• (1S)-1,25-dihydroxy-24-oxocalciol + 2 reduced [adrenodoxin] + O2 + 2 H(+) = (1S)-1,23,25-trihydroxy-24-oxocalciol + 2 oxidized [adrenodoxin] + H2O (RHEA:24976)
• (1S)-1,23-dihydroxy-24,25,26,27-tetranorcalciol + 2 reduced [adrenodoxin] + O2 + 2 H(+) = (1S)-1-hydroxy-23-oxo-24,25,26,27-tetranorcalciol + 2 oxidized [adrenodoxin] + 2 H2O (RHEA:24984)
• (1S)-1-hydroxy-23-oxo-24,25,26,27-tetranorcalciol + 2 reduced [adrenodoxin] + O2 + H(+) = calcitroate + 2 oxidized [adrenodoxin] + H2O (RHEA:24988)
• calcidiol + 2 reduced [adrenodoxin] + O2 + 2 H(+) = (23S)-23,25-dihydroxycalciol + 2 oxidized [adrenodoxin] + H2O (RHEA:46616)
• calcitriol + 2 reduced [adrenodoxin] + O2 + 2 H(+) = 1alpha,23S,25-trihydroxycholecalciferol + 2 oxidized [adrenodoxin] + H2O (RHEA:49192)
• secalciferol + 2 reduced [adrenodoxin] + O2 + 2 H(+) = 25-hydroxy-24-oxocalciol + 2 oxidized [adrenodoxin] + 2 H2O (RHEA:49196)
• 20S-hydroxycholecalciferol + 2 reduced [adrenodoxin] + O2 + 2 H(+) = 20S,24R-dihydroxycholecalciferol + 2 oxidized [adrenodoxin] + H2O (RHEA:49204)
• 20S-hydroxycholecalciferol + 2 reduced [adrenodoxin] + O2 + 2 H(+) = 20S,25-dihydroxycholecalciferol + 2 oxidized [adrenodoxin] + H2O (RHEA:49212)
• 25-hydroxy-24-oxocalciol + 2 reduced [adrenodoxin] + O2 + 2 H(+) = 23S,25-dihydroxy-24-oxocholecalciferol + 2 oxidized [adrenodoxin] + H2O (RHEA:49268)

UniProt features (20 total): sequence variant 7, sequence conflict 7, splice variant 3, transit peptide 1, chain 1, binding site 1

Structure

Experimental structures (PDB)

0 structures.

Predicted structure (AlphaFold)

Model	pLDDT	Fraction very-high
AF-Q07973-F1	89.03	0.78

Functional residue map

Curated UniProt residues grouped by drug-discovery relevance — catalytic, ligand-binding, modification, and mutation-validated positions. Source: UniProtKB sequence features.

Ligand- & substrate-binding residues (1): 462 (axial binding residue)

Function

Pathways and Gene Ontology

Reactome pathways

3 pathways

ID	Pathway
R-HSA-196791	Vitamin D (calciferol) metabolism
R-HSA-211916	Vitamins
R-HSA-5579010	Defective CYP24A1 causes HCAI

MSigDB gene sets: 242 (showing top): REACTOME_BIOLOGICAL_OXIDATIONS, BUYTAERT_PHOTODYNAMIC_THERAPY_STRESS_DN, BENPORATH_ES_WITH_H3K27ME3, GOMF_OXIDOREDUCTASE_ACTIVITY_ACTING_ON_PAIRED_DONORS_WITH_INCORPORATION_OR_REDUCTION_OF_MOLECULAR_OXYGEN, GOBP_CELLULAR_RESPONSE_TO_LIPID, SHEPARD_CRASH_AND_BURN_MUTANT_UP, GRAESSMANN_APOPTOSIS_BY_SERUM_DEPRIVATION_DN, GOBP_POLYOL_METABOLIC_PROCESS, GRAESSMANN_APOPTOSIS_BY_DOXORUBICIN_DN, GOBP_OSTEOBLAST_DIFFERENTIATION, LINDGREN_BLADDER_CANCER_CLUSTER_3_DN, NAGASHIMA_NRG1_SIGNALING_UP, GOBP_CELLULAR_RESPONSE_TO_OXYGEN_CONTAINING_COMPOUND, TTGCWCAAY_CEBPB_02, GOBP_SMALL_MOLECULE_BIOSYNTHETIC_PROCESS

GO Biological Process (12): osteoblast differentiation (GO:0001649), vitamin metabolic process (GO:0006766), response to vitamin D (GO:0033280), vitamin D metabolic process (GO:0042359), vitamin D catabolic process (GO:0042369), vitamin D receptor signaling pathway (GO:0070561), alcohol metabolic process (GO:0006066), lipid metabolic process (GO:0006629), lipid biosynthetic process (GO:0008610), calcitriol biosynthetic process from calciol (GO:0036378), small molecule biosynthetic process (GO:0044283), cellular response to vitamin D (GO:0071305)

GO Molecular Function (12): iron ion binding (GO:0005506), 25-hydroxycholecalciferol-24-hydroxylase activity (GO:0008403), heme binding (GO:0020037), 1-alpha,25-dihydroxyvitamin D3 24-hydroxylase activity (GO:0030342), vitamin D 25-hydroxylase activity (GO:0030343), 25-hydroxycholecalciferol-23-hydroxylase activity (GO:0062180), 1-alpha,25-dihydroxyvitamin D3 23-hydroxylase activity (GO:0062181), monooxygenase activity (GO:0004497), oxidoreductase activity (GO:0016491), oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen (GO:0016705), metal ion binding (GO:0046872), vitamin D 24-hydroxylase activity (GO:0070576)

GO Cellular Component (2): mitochondrion (GO:0005739), mitochondrial inner membrane (GO:0005743)

Reactome top-level categories

Rollup of top-3 pathways:

Category	Pathways
Metabolism of steroids	1
Cytochrome P450 - arranged by substrate type	1
Metabolic disorders of biological oxidation enzymes	1

GO top-level categories

Rollup of top GO terms by namespace:

Category	Terms
small molecule metabolic process	3
biosynthetic process	2
vitamin D 24-hydroxylase activity	2
steroid hydroxylase activity	2
vitamin D 23-hydroxylase activity	2
oxidoreductase activity	2
ossification	1
cell differentiation	1
response to vitamin	1
response to lipid	1
response to oxygen-containing compound	1
steroid metabolic process	1
steroid catabolic process	1
vitamin D metabolic process	1
fat-soluble vitamin catabolic process	1
hormone-mediated signaling pathway	1
cellular response to vitamin D	1
nuclear receptor-mediated signaling pathway	1
primary metabolic process	1
lipid metabolic process	1
vitamin D biosynthetic process	1
polyol biosynthetic process	1
vitamin D3 metabolic process	1
response to vitamin D	1
cellular response to vitamin	1
cellular response to lipid	1
cellular response to oxygen-containing compound	1
transition metal ion binding	1
oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen	1
tetrapyrrole binding	1
calcitriol biosynthetic process from calciol	1
catalytic activity	1
cation binding	1
cytoplasm	1
intracellular membrane-bounded organelle	1
organelle inner membrane	1
mitochondrial membrane	1

Protein interactions and networks

STRING

2026 interactions, top by confidence (×1000):

Protein A	Protein B	Partner UniProt	Score
CYP24A1	GC	P02774	897
CYP24A1	CA1	P00915	879
CYP24A1	CA8	P35219	870
CYP24A1	CA5B	Q9Y2D0	870
CYP24A1	CA13	Q8N1Q1	848
CYP24A1	PTH	P01270	842
CYP24A1	CA5A	P35218	841
CYP24A1	CA14	Q9ULX7	841
CYP24A1	CA7	P43166	819
CYP24A1	CA6	P23280	806
CYP24A1	CA12	O43570	799
CYP24A1	FGF23	Q9GZV9	793
CYP24A1	CA2	P00918	792
CYP24A1	DHCR7	Q9UBM7	783
CYP24A1	CA3	P07451	779

IntAct

57 interactions, top by confidence:

A	B	Type	Score
NDUFS6	NDUFS8	psi-mi:“MI:0914”(association)	0.640
PTGR3	DBT	psi-mi:“MI:0914”(association)	0.640
ZNF764	SH3PXD2B	psi-mi:“MI:0914”(association)	0.530
UQCRFS1	NDUFAB1	psi-mi:“MI:0914”(association)	0.530
AGMAT	DCX	psi-mi:“MI:0914”(association)	0.500
Dlg4	CYP24A1	psi-mi:“MI:0407”(direct interaction)	0.440
ECSIT	NDUFS2	psi-mi:“MI:0914”(association)	0.350
ZNF254	TRIM24	psi-mi:“MI:0914”(association)	0.350
ZNF785	CASK	psi-mi:“MI:0914”(association)	0.350
PA	ESYT2	psi-mi:“MI:0914”(association)	0.350
THEM5	PRORP	psi-mi:“MI:0914”(association)	0.350
RBAK	CYP24A1	psi-mi:“MI:0914”(association)	0.350
MRPS7	RPSA2	psi-mi:“MI:0914”(association)	0.350
FFAR1	SLC12A8	psi-mi:“MI:0914”(association)	0.350
GPR182	SLC12A8	psi-mi:“MI:0914”(association)	0.350
TRIM43	VWA8	psi-mi:“MI:0914”(association)	0.350
QRSL1	VWA8	psi-mi:“MI:0914”(association)	0.350
SHC2	VWA8	psi-mi:“MI:0914”(association)	0.350
YARS2	VWA8	psi-mi:“MI:0914”(association)	0.350
MRPS24	VWA8	psi-mi:“MI:0914”(association)	0.350
AMACR	VWA8	psi-mi:“MI:0914”(association)	0.350
ACSM5	VWA8	psi-mi:“MI:0914”(association)	0.350
RASL10B	VWA8	psi-mi:“MI:0914”(association)	0.350
AK4	VWA8	psi-mi:“MI:0914”(association)	0.350
FAHD1	VWA8	psi-mi:“MI:0914”(association)	0.350
GPR45	VWA8	psi-mi:“MI:0914”(association)	0.350
THEM5	GTPBP10	psi-mi:“MI:0914”(association)	0.350
MALSU1	GTPBP10	psi-mi:“MI:0914”(association)	0.350

BioGRID (60): CYP24A1 (Affinity Capture-MS), CYP24A1 (Affinity Capture-MS), CYP24A1 (Affinity Capture-MS), CYP24A1 (Affinity Capture-MS), CYP24A1 (Synthetic Lethality), CYP24A1 (Proximity Label-MS), FZR1 (Affinity Capture-Western), CDC20 (Affinity Capture-Western), CYP24A1 (Affinity Capture-MS), CYP24A1 (Affinity Capture-MS), CYP24A1 (Affinity Capture-MS), CYP24A1 (Affinity Capture-MS), CYP24A1 (Affinity Capture-MS), CYP24A1 (Affinity Capture-MS), CYP24A1 (Affinity Capture-MS)

ESM2 similar proteins: A0A1I9Q5Z0, A0A481NR20, A8WGA0, E1BHJ4, G3V7X8, O18635, O23051, O44220, O73853, P05093, P0DOX0, P11715, P48416, P82712, Q07973, Q09128, Q09660, Q2XVA1, Q4G0S4, Q64441, Q6JD68, Q6WG30, Q7KR10, Q811W2, Q8HYM9, Q8HYN0, Q8HYN1, Q8W4T9, Q91Z85, Q92045, Q92113, Q940V4, Q95328, Q9EPT4, Q9GLD2, Q9GMC8, Q9LUC5, Q9NGX9, Q9NR63, Q9SHG5

Diamond homologs: A0A017SFB8, A0A017SR40, A0A0C3HJL3, A0A0S2II38, A0A0U5GRB4, A0A100IM63, A0A1E3B0R7, A0A1L9WN72, A0A1L9WQP6, A0A1L9WUS5, A0A1U9YHZ8, A0A1V0QSE7, A0A2H3CNY6, A0A2H3CSA7, A0A2H3CZX2, A0A2P1DP94, A0A2Z5U6I9, A0A3Q7HBJ5, A0A516F411, A0A6J4BC30, A0A6S6QI82, A0A7T8F1L2, A1DA63, A7VMU4, A8NCK4, A8NCK6, A9QNE7, B9WZX4, C8VJR0, F1SY52, F1SY62, F1SY66, F1SY68, F1SY70, F1SY73, F1SY75, F1SY82, F1SY91, F1SY96, F1SYA2

SIGNOR signaling

5 interactions.

A	Effect	B	Mechanism
VDR	“down-regulates quantity by repression”	CYP24A1	“transcriptional regulation”
PTH1R	“up-regulates quantity”	CYP24A1
CYP24A1	“up-regulates quantity”	calcitetrol	“chemical modification”
CYP24A1	“down-regulates quantity”	calcitriol	“chemical modification”
CYP24A1	“up-regulates quantity”	propan-2-ol	“chemical modification”

Enriched among interaction partners

Reactome pathways and GO biological processes over-represented among this gene’s 83 IntAct physical interaction partners (hypergeometric vs the genome-wide background, BH-FDR, gene-set size 15–500, ranked by fold). A functional readout of the neighbourhood — distinct from this gene’s own memberships above, and biased toward well-studied / hub proteins, so read it as themes rather than proof.

Reactome pathways:

Pathway	Partners	Fold	FDR
Complex I biogenesis	6	17.4×	2e-04
Mitochondrial ribosome-associated quality control	6	12.9×	7e-04
Fatty acid metabolism	5	11.5×	3e-03
Respiratory electron transport	6	10.0×	2e-03

GO biological processes:

GO term	Partners	Fold	FDR
mitochondrial respiratory chain complex I assembly	5	27.4×	3e-04
mitochondrial electron transport, NADH to ubiquinone	5	23.9×	3e-04
proton motive force-driven mitochondrial ATP synthesis	5	17.6×	1e-03
aerobic respiration	5	16.5×	1e-03
mitochondrial translation	5	11.6×	4e-03

Disease & clinical

Clinical variants and AI predictions

ClinVar

460 variants total. Per-class counts are floors (≥ shown; pagination cap):

Classification	Count (floor)
Pathogenic	31
Likely pathogenic	23
Uncertain significance	210
Likely benign	80
Benign	63

Top pathogenic / likely-pathogenic (30)

Variant ID	HGVS	Classification
1072834	NM_000782.5(CYP24A1):c.1396C>T (p.Arg466Ter)	Pathogenic
1075791	NM_000782.5(CYP24A1):c.278del (p.Tyr93fs)	Pathogenic
1179111	GRCh37/hg19 20q13.2(chr20:52769985-52790525)	Pathogenic
1442407	NM_000782.5(CYP24A1):c.312del (p.Phe104fs)	Pathogenic
1460149	NM_000782.5(CYP24A1):c.999_1006del (p.Ser334fs)	Pathogenic
1914788	NM_000782.5(CYP24A1):c.1171_1174dup (p.Pro392fs)	Pathogenic
1941936	NM_000782.5(CYP24A1):c.1384_1385del (p.Cys462fs)	Pathogenic
2111621	NM_000782.5(CYP24A1):c.224G>A (p.Trp75Ter)	Pathogenic
2159550	NM_000782.5(CYP24A1):c.449+1G>T	Pathogenic
2506936	NM_000782.5(CYP24A1):c.641-1G>A	Pathogenic
2506945	NM_000782.5(CYP24A1):c.364G>T (p.Glu122Ter)	Pathogenic
2912919	NM_000782.5(CYP24A1):c.1022del (p.Asn341fs)	Pathogenic
29675	NM_000782.5(CYP24A1):c.1426_1427del (p.Cys477fs)	Pathogenic
29677	NM_000782.5(CYP24A1):c.425AAG[1] (p.Glu143del)	Pathogenic
29678	NM_000782.5(CYP24A1):c.451G>T (p.Glu151Ter)	Pathogenic
2993674	NM_000782.5(CYP24A1):c.449+2T>C	Pathogenic
3234027	NM_000782.5(CYP24A1):c.109C>T (p.Gln37Ter)	Pathogenic
3236073	NM_000782.5(CYP24A1):c.1320G>A (p.Trp440Ter)	Pathogenic
3236225	NM_000782.5(CYP24A1):c.670_673dup (p.Gly225fs)	Pathogenic
3248320	NC_000020.10:g.(?52773718)(52790118_?)del	Pathogenic
3341138	NM_000782.5(CYP24A1):c.1039del (p.Gln347fs)	Pathogenic
3587448	NM_000782.5(CYP24A1):c.845-2A>G	Pathogenic
3587450	NM_000782.5(CYP24A1):c.804G>A (p.Trp268Ter)	Pathogenic
3587457	NM_000782.5(CYP24A1):c.667A>T (p.Arg223Ter)	Pathogenic
3608266	NM_000782.5(CYP24A1):c.1497_1504del (p.Thr500fs)	Pathogenic
3623870	NM_000782.5(CYP24A1):c.1084G>T (p.Glu362Ter)	Pathogenic
3642651	NM_000782.5(CYP24A1):c.491del (p.Lys164fs)	Pathogenic
3708845	NM_000782.5(CYP24A1):c.1199del (p.Lys400fs)	Pathogenic
4074266	NM_000782.5(CYP24A1):c.1339dup (p.Ile447fs)	Pathogenic
4294430	NM_000782.5(CYP24A1):c.1410dup (p.Gln471fs)	Pathogenic

SpliceAI

1723 predictions. Top by Δscore:

Variant	Effect	Δscore
20:54157163:GCTCA:G	donor_loss	1.0000
20:54157164:CTCA:C	donor_loss	1.0000
20:54157165:TCACC:T	donor_loss	1.0000
20:54157166:CACCT:C	donor_loss	1.0000
20:54157167:A:AG	donor_loss	1.0000
20:54157168:C:T	donor_loss	1.0000
20:54157286:CAAT:C	acceptor_gain	1.0000
20:54157288:ATC:A	acceptor_loss	1.0000
20:54157290:C:CC	acceptor_gain	1.0000
20:54157290:C:CG	acceptor_loss	1.0000
20:54157291:T:G	acceptor_loss	1.0000
20:54157295:A:AC	acceptor_gain	1.0000
20:54158080:ACTTA:A	donor_loss	1.0000
20:54158082:TTA:T	donor_loss	1.0000
20:54158084:A:AC	donor_gain	1.0000
20:54158084:A:C	donor_loss	1.0000
20:54158084:ACT:A	donor_gain	1.0000
20:54158084:ACTC:A	donor_gain	1.0000
20:54158085:C:CT	donor_gain	1.0000
20:54158085:CT:C	donor_gain	1.0000
20:54158085:CTC:C	donor_gain	1.0000
20:54158085:CTCC:C	donor_gain	1.0000
20:54158085:CTCCT:C	donor_gain	1.0000
20:54158160:TAAGC:T	acceptor_gain	1.0000
20:54158162:AGC:A	acceptor_gain	1.0000
20:54158163:GC:G	acceptor_gain	1.0000
20:54158163:GCCT:G	acceptor_loss	1.0000
20:54158164:CC:C	acceptor_gain	1.0000
20:54158164:CCTGA:C	acceptor_loss	1.0000
20:54158165:C:CC	acceptor_gain	1.0000

AlphaMissense

3371 scored. Top likely-pathogenic:

Variant	Protein change	am_pathogenicity
20:54172945:C:G	R138P	0.996
20:54172958:A:G	W134R	0.995
20:54172958:A:T	W134R	0.995
20:54158135:C:G	R396P	0.994
20:54157457:A:C	F455L	0.991
20:54157457:A:T	F455L	0.991
20:54157459:A:G	F455L	0.991
20:54169604:A:G	W210R	0.991
20:54169604:A:T	W210R	0.991
20:54171644:C:G	R159P	0.991
20:54164473:A:G	W275R	0.990
20:54164473:A:T	W275R	0.990
20:54172946:G:T	R138S	0.990
20:54157442:T:A	R460S	0.988
20:54157442:T:G	R460S	0.988
20:54158957:C:G	R386T	0.988
20:54164494:A:G	W268R	0.988
20:54164494:A:T	W268R	0.988
20:54171657:A:G	W155R	0.988
20:54171657:A:T	W155R	0.988
20:54158164:C:A	R386S	0.987
20:54158164:C:G	R386S	0.987
20:54171655:C:A	W155C	0.987
20:54171655:C:G	W155C	0.987
20:54157436:G:C	C462W	0.986
20:54165832:A:C	S214R	0.986
20:54165832:A:T	S214R	0.986
20:54169592:T:G	S214R	0.986
20:54157428:C:G	R465P	0.985
20:54159112:A:C	S334R	0.985

dbSNP variants (sampled 300 via entrez): RS1000010588 (20:54152489 G>A), RS1000127032 (20:54159103 C>A,T), RS1000176915 (20:54159667 G>C), RS1000190807 (20:54146530 C>T), RS1000293051 (20:54152717 GA>G), RS1000537278 (20:54174149 G>A), RS1000612850 (20:54163298 T>C), RS1000649174 (20:54153974 C>A), RS1000895799 (20:54163613 G>C), RS1001012457 (20:54164182 C>G,T), RS1001078060 (20:54174411 C>A,T), RS1001152932 (20:54158238 A>G), RS1001184296 (20:54158533 T>A,C), RS1001351315 (20:54146300 G>A,T), RS1001379856 (20:54163916 A>C)

Disease associations

OMIM: gene MIM:126065 | disease phenotypes: MIM:143880

GenCC curated gene-disease

Disease	Classification	Inheritance
hypercalcemia, infantile, 1	Strong	Autosomal recessive
autosomal recessive infantile hypercalcemia	Supportive	Autosomal recessive

Mondo (2): hypercalcemia, infantile, 1 (MONDO:0020739), (MONDO:0007749)

Orphanet (1): Autosomal recessive infantile hypercalcemia (Orphanet:300547)

HPO phenotypes

15 total (15 of 15 shown, HPO-id order):

HPO	Term
HP:0000007	Autosomal recessive inheritance
HP:0000103	Polyuria
HP:0000121	Nephrocalcinosis
HP:0000787	Nephrolithiasis
HP:0001252	Hypotonia
HP:0001254	Lethargy
HP:0001508	Failure to thrive
HP:0001824	Weight loss
HP:0001944	Dehydration
HP:0002013	Vomiting
HP:0002150	Hypercalciuria
HP:0003072	Hypercalcemia
HP:0003593	Infantile onset
HP:0012408	Medullary nephrocalcinosis
HP:0031817	Decreased circulating parathyroid hormone level

GWAS associations

27 associations (top):

Study	Trait	p-value
GCST001198_43	Multiple sclerosis	3.000000e-11
GCST001709_17	Atopic dermatitis	2.000000e-08
GCST002201_7	Calcium levels	9.000000e-12
GCST003262_352	Post bronchodilator FEV1	3.000000e-06
GCST003386_1	Colorectal cancer (oestrogen-progestogen hormone therapy interaction)	5.000000e-09
GCST003879_1	Serum parathyroid hormone levels	2.000000e-10
GCST003879_2	Serum parathyroid hormone levels	2.000000e-72
GCST005366_4	Vitamin D levels (dietary vitamin D intake interaction)	1.000000e-14
GCST005367_6	Vitamin D levels	8.000000e-23
GCST005531_70	Multiple sclerosis	2.000000e-13
GCST005982_15	Calcium levels	1.000000e-09
GCST006491_19	Circulating fibroblast growth factor 23 levels	3.000000e-24
GCST007876_52	Estimated glomerular filtration rate	1.000000e-17
GCST007877_24	Creatinine levels	1.000000e-08
GCST008058_160	Estimated glomerular filtration rate	2.000000e-46
GCST008059_121	Estimated glomerular filtration rate	4.000000e-50
GCST008062_130	Blood urea nitrogen levels	6.000000e-08
GCST008369_19	Plasma anti-thyroglobulin levels	2.000000e-06
GCST008745_29	Estimated glomerular filtration rate in non-diabetics	1.000000e-14
GCST008747_121	Estimated glomerular filtration rate	3.000000e-25
GCST008747_92	Estimated glomerular filtration rate	1.000000e-36
GCST009597_52	Multiple sclerosis	2.000000e-19
GCST009597_92	Multiple sclerosis	2.000000e-06
GCST009598_18	Kidney stones	8.000000e-18
GCST009599_12	Kidney stones	1.000000e-11
GCST010219_21	Attention deficit hyperactivity disorder (inattention symptoms)	3.000000e-07
GCST90011900_10	Serum alkaline phosphatase levels	7.000000e-09

EFO canonical traits (5, from GWAS)

EFO ID	Trait name
EFO:0004838	calcium measurement
EFO:0004314	forced expiratory volume
EFO:0003961	hormone replacement therapy
EFO:0008539	vitamin D dietary intake measurement
EFO:0004533	alkaline phosphatase measurement

Drugs & pharmacology

Drug and pharmacology data

Is drug target: yes

ChEMBL targets (1): CHEMBL4521 (SINGLE PROTEIN)

Molecules with ChEMBL bioactivity

4 molecules (phase ≥1), by development phase (incl. off-target/promiscuous compounds). Patent mentions across the top 20 by phase: 119,592 (via chembl_molecule»patent_compound — counts attach to the compound, not the gene–compound relationship, so off-target/promiscuous molecules can dominate).

Molecule	Name	Phase	Patents
CHEMBL157101	KETOCONAZOLE	4	75,361
CHEMBL846	CALCITRIOL	4	29,522
CHEMBL2105705	LUNACALCIPOL	2	73
CHEMBL389433	LIAROZOLE	2	14,636

PharmGKB: 1 entry (VIP=true, CPIC=false)

PharmGKB clinical annotations

5 annotations.

Variant	Type	Level	Drugs	Phenotypes
rs2248359	Metabolism/PK	3	deferasirox	Beta-thalassemia and related diseases
rs2248359	Toxicity	3	tenofovir disoproxil fumarate	HIV infectious disease;Nephrotoxicity
rs2585428	Metabolism/PK	3	telaprevir	Hepatitis C virus infection
rs2585428	Metabolism/PK	3	deferasirox	Beta-thalassemia and related diseases
rs927650	Metabolism/PK	3	deferasirox	Beta-thalassemia and related diseases

PharmGKB variants

6 variants.

Variant	Genes	Level	Score	#Clin annots	Drugs
rs2585428	CYP24A1	3	2.00	2	deferasirox;telaprevir
rs2762939	CYP24A1		0.00	0
rs3787554	CYP24A1		0.00	0
rs4809957	CYP24A1		0.00	0
rs2248359	CYP24A1	3	2.25	2	tenofovir disoproxil fumarate;deferasirox
rs927650	CYP24A1	3	1.25	1	deferasirox

GtoPdb / IUPHAR curated pharmacology

(IUPHAR/BPS Guide to Pharmacology — expert-curated)

Target class: enzyme — CYP24, CYP26 and CYP27 families

Most potent curated ligand interactions (3 total), top 3:

Ligand	Action	Affinity	Parameter
CTA091	Inhibition	8.2	pIC50
lunacalcipol	Inhibition	7.6	pIC50
compound 4d [PMID: 20655626]	Inhibition	4.79	pIC50

Binding affinities (BindingDB)

6 measured of 6 human assays (6 total across all organisms); most potent 6 below. Values come from heterogeneous assays and are not directly comparable.

Ligand	Measure	Value
AB47	KI	21 nM
VIMI	KI	21 nM
24F2-1,25(OH)D3	KI	24 nM
TS17	KI	39 nM
CPA1	KI	42 nM
24COOH-25(OH)D3	KI	90 nM

ChEMBL bioactivities

117 potent at pChembl≥5 of 128 total, top 50 by pChembl (potency: 10 = 0.1 nM, 6 = 1 µM).

pChembl	Type	Value	Unit	Molecule
8.64	IC50	2.3	nM	LIAROZOLE
8.53	EC50	2.96	nM	CHEMBL5182683
8.52	EC50	3.02	nM	CALCITRIOL
8.25	EC50	5.6	nM	CHEMBL5175578
8.19	IC50	6.5	nM	CHEMBL389014
8.13	IC50	7.4	nM	CHEMBL389014
8.13	IC50	7.4	nM	CHEMBL255088
8.11	Ki	7.8	nM	CHEMBL3329769
8.01	Ki	9.7	nM	CHEMBL3329770
8.01	IC50	9.7	nM	CHEMBL1627206
7.96	Ki	11	nM	CHEMBL3329774
7.89	Ki	13	nM	CHEMBL3329778
7.89	IC50	13	nM	CHEMBL1627206
7.85	Ki	14	nM	CHEMBL3344394
7.85	Ki	14	nM	CHEMBL3344395
7.82	IC50	15	nM	CHEMBL1170908
7.82	IC50	15.2	nM	CHEMBL1170908
7.82	IC50	15	nM	CHEMBL253613
7.82	IC50	15.1	nM	CHEMBL1170908
7.72	Ki	19	nM	CHEMBL3329767
7.69	IC50	20.5	nM	CHEMBL1627203
7.68	Ki	21	nM	CHEMBL3360784
7.62	Ki	24	nM	CHEMBL3329768
7.58	Ki	26	nM	CHEMBL3344392
7.57	IC50	27	nM	LUNACALCIPOL
7.57	IC50	27	nM	CHEMBL4797263
7.55	Ki	28	nM	CHEMBL1171494
7.55	IC50	28	nM	CHEMBL224719
7.55	IC50	28	nM	CHEMBL1627207
7.55	IC50	28	nM	CHEMBL389014
7.51	Ki	31	nM	CHEMBL3344393
7.48	Ki	33	nM	KETOCONAZOLE
7.46	Ki	35	nM	KETOCONAZOLE
7.44	Ki	36	nM	CHEMBL3329771
7.43	Ki	37	nM	CHEMBL3344396
7.43	Ki	37	nM	CHEMBL3344397
7.41	Ki	39	nM	CHEMBL3360783
7.38	Ki	42	nM	CHEMBL3329779
7.38	Ki	42	nM	CHEMBL3360785
7.36	IC50	44	nM	CHEMBL1627207
7.30	IC50	50	nM	CHEMBL1627203
7.12	IC50	75	nM	CHEMBL1627204
7.04	Ki	91	nM	CHEMBL3329772
6.96	IC50	110	nM	CHEMBL3329769
6.96	IC50	110	nM	CHEMBL4105510
6.92	IC50	120	nM	CHEMBL4080128
6.90	IC50	126	nM	KETOCONAZOLE
6.85	IC50	140	nM	CHEMBL3329770
6.82	Ki	150	nM	CHEMBL3329773
6.82	IC50	150	nM	CHEMBL4066700

PubChem BioAssay actives

124 with measured affinity, of 176 total; 50 most potent distinct compounds. Largely complementary to BindingDB; screening values are coarse (µM, 4 dp), so sub-nM hits tie at the floor.

Compound	Assay	Type	Value	Unit
6-[(3-chlorophenyl)-imidazol-1-ylmethyl]-1H-benzimidazole	1160913: Inhibition of human MBP-tagged CYP24A1 expressed in Escherichia coli using 1,25(OH)2D3 substrate in presence of bovine adrenodoxin, adrenodoxin reductase and NADPH incubated at 37 degC for 25 mins by HPLC method	ic50	0.0023	uM
trans-(1R,3S,5Z)-5-[(E)-3-[3,5-bis(6-hydroxy-6-methylheptyl)phenyl]prop-2-enylidene]-4-methylidenecyclohexane-1,3-diol	1852313: Induction of CYP24A1 (unknown orgin) transcriptional activity trasfected in human MCF7 cells incuabted for 48 hrs by luciferase reporter gene assay	ec50	0.0030	uM
Calcitriol	1852313: Induction of CYP24A1 (unknown orgin) transcriptional activity trasfected in human MCF7 cells incuabted for 48 hrs by luciferase reporter gene assay	ec50	0.0030	uM
trans-(1R,3S,5Z)-5-[(E)-9-hydroxy-3-[3-(6-hydroxy-6-methylheptyl)phenyl]-9-methyldec-2-enylidene]-4-methylidenecyclohexane-1,3-diol	1852313: Induction of CYP24A1 (unknown orgin) transcriptional activity trasfected in human MCF7 cells incuabted for 48 hrs by luciferase reporter gene assay	ec50	0.0056	uM
trans-(1R,3S,5Z)-5-[(2E)-2-[(1R,3aS,7aR)-7a-methyl-1-[(2R)-4-(phenylsulfonimidoyl)butan-2-yl]-2,3,3a,5,6,7-hexahydro-1H-inden-4-ylidene]ethylidene]-4-methylidenecyclohexane-1,3-diol	1160913: Inhibition of human MBP-tagged CYP24A1 expressed in Escherichia coli using 1,25(OH)2D3 substrate in presence of bovine adrenodoxin, adrenodoxin reductase and NADPH incubated at 37 degC for 25 mins by HPLC method	ic50	0.0065	uM
trans-(1R,3S,5Z)-5-[(2E)-2-[(7aS)-7a-methyl-1-[(2R)-4-(phenylsulfonimidoyl)butan-2-yl]-3a,5,6,7-tetrahydro-3H-inden-4-ylidene]ethylidene]-4-methylidenecyclohexane-1,3-diol	311066: Inhibition of CYP24	ic50	0.0074	uM
4-[(E)-2-(3,5-dimethoxyphenyl)ethenyl]-N-(2-imidazol-1-yl-2-phenylethyl)benzamide	1160913: Inhibition of human MBP-tagged CYP24A1 expressed in Escherichia coli using 1,25(OH)2D3 substrate in presence of bovine adrenodoxin, adrenodoxin reductase and NADPH incubated at 37 degC for 25 mins by HPLC method	ki	0.0078	uM
trans-(1R,3R)-5-[(2E)-2-[(1R,3aS,7aR)-7a-methyl-1-[(2R)-4-(phenylsulfonimidoyl)butan-2-yl]-2,3,3a,5,6,7-hexahydro-1H-inden-4-ylidene]ethylidene]cyclohexane-1,3-diol	282480: Inhibition of human CYP24 hydroxylase expressed in V79 cells	ic50	0.0097	uM
N-(2-imidazol-1-yl-2-phenylethyl)-4-[(E)-2-(3,4,5-trimethoxyphenyl)ethenyl]benzamide	1160913: Inhibition of human MBP-tagged CYP24A1 expressed in Escherichia coli using 1,25(OH)2D3 substrate in presence of bovine adrenodoxin, adrenodoxin reductase and NADPH incubated at 37 degC for 25 mins by HPLC method	ki	0.0097	uM
[1-[4-[(E)-2-(3,5-dimethoxyphenyl)ethenyl]phenyl]-4,4-dimethylpentan-3-yl] imidazole-1-carboxylate	1160913: Inhibition of human MBP-tagged CYP24A1 expressed in Escherichia coli using 1,25(OH)2D3 substrate in presence of bovine adrenodoxin, adrenodoxin reductase and NADPH incubated at 37 degC for 25 mins by HPLC method	ki	0.0110	uM
(Z)-2-imidazol-1-yl-4,4-dimethyl-1-[4-[(E)-2-phenylethenyl]phenyl]pent-1-en-3-one	1160913: Inhibition of human MBP-tagged CYP24A1 expressed in Escherichia coli using 1,25(OH)2D3 substrate in presence of bovine adrenodoxin, adrenodoxin reductase and NADPH incubated at 37 degC for 25 mins by HPLC method	ki	0.0130	uM
1-(4-imidazol-1-ylbutyl)-4-[(E)-2-phenylethenyl]indole	1165071: Inhibition of N-terminally MBP-fused human CYP24A1 by cell-free assay	ki	0.0140	uM
4-[(E)-2-(3,5-dimethoxyphenyl)ethenyl]-1-(4-imidazol-1-ylbutyl)indole	1165071: Inhibition of N-terminally MBP-fused human CYP24A1 by cell-free assay	ki	0.0140	uM
4-(4-chlorophenyl)-N-[(2R)-2-imidazol-1-yl-2-phenylethyl]benzamide	1160913: Inhibition of human MBP-tagged CYP24A1 expressed in Escherichia coli using 1,25(OH)2D3 substrate in presence of bovine adrenodoxin, adrenodoxin reductase and NADPH incubated at 37 degC for 25 mins by HPLC method	ic50	0.0150	uM
4-(4-chlorophenyl)-N-(2-imidazol-1-yl-2-phenylethyl)benzamide	311064: Inhibition of CYP24 in human keratinocytes	ic50	0.0150	uM
4-[(E)-2-(4-fluorophenyl)ethenyl]-N-(2-imidazol-1-yl-2-phenylethyl)benzamide	1160913: Inhibition of human MBP-tagged CYP24A1 expressed in Escherichia coli using 1,25(OH)2D3 substrate in presence of bovine adrenodoxin, adrenodoxin reductase and NADPH incubated at 37 degC for 25 mins by HPLC method	ki	0.0190	uM
trans-(1R,3S,5Z)-5-[(2E)-2-[(1R,3aS,7aR)-7a-methyl-1-[(2R)-1-[1-(phenylsulfonimidoyl)cyclopropyl]propan-2-yl]-2,3,3a,5,6,7-hexahydro-1H-inden-4-ylidene]ethylidene]-4-methylidenecyclohexane-1,3-diol	282480: Inhibition of human CYP24 hydroxylase expressed in V79 cells	ic50	0.0205	uM
trans-(1R,3R)-5-[(2E)-2-[(1R,3aS,7aR)-1-[(2S)-1-imidazol-1-ylpropan-2-yl]-7a-methyl-2,3,3a,5,6,7-hexahydro-1H-inden-4-ylidene]ethylidene]-2-methylidenecyclohexane-1,3-diol	1160913: Inhibition of human MBP-tagged CYP24A1 expressed in Escherichia coli using 1,25(OH)2D3 substrate in presence of bovine adrenodoxin, adrenodoxin reductase and NADPH incubated at 37 degC for 25 mins by HPLC method	ki	0.0210	uM
[(2R)-2-[(4E,7aR)-4-[(2Z)-2-[(5R)-5-hydroxy-2-methylidenecyclohexylidene]ethylidene]-7a-methyl-2,3,3a,5,6,7-hexahydro-1H-inden-1-yl]propyl] 2-bromoacetate	1799837: CYP24A1Inhibition Assay from Article 10.1021/bi101488p: “Screening of selective inhibitors of 1a,25-dihydroxyvitamin D3 24-hydroxylase using recombinant human enzyme expressed in Escherichia coli.”	ki	0.0210	uM
cis-(1S,3R)-5-[(2E)-2-[(7aR)-1-[(2R)-1-imidazol-1-ylpropan-2-yl]-7a-methyl-2,3,3a,5,6,7-hexahydro-1H-inden-4-ylidene]ethylidene]-2-methylidenecyclohexane-1,3-diol	1799837: CYP24A1Inhibition Assay from Article 10.1021/bi101488p: “Screening of selective inhibitors of 1a,25-dihydroxyvitamin D3 24-hydroxylase using recombinant human enzyme expressed in Escherichia coli.”	ki	0.0210	uM
N-(2-imidazol-1-yl-2-phenylethyl)-4-[(E)-2-(4-methoxyphenyl)ethenyl]benzamide	1160913: Inhibition of human MBP-tagged CYP24A1 expressed in Escherichia coli using 1,25(OH)2D3 substrate in presence of bovine adrenodoxin, adrenodoxin reductase and NADPH incubated at 37 degC for 25 mins by HPLC method	ki	0.0240	uM
1-[4-[4-[[(2R,4S)-2-(2,4-dichlorophenyl)-2-(imidazol-1-ylmethyl)-1,3-dioxolan-4-yl]methoxy]phenyl]piperazin-1-yl]ethanone	1799837: CYP24A1Inhibition Assay from Article 10.1021/bi101488p: “Screening of selective inhibitors of 1a,25-dihydroxyvitamin D3 24-hydroxylase using recombinant human enzyme expressed in Escherichia coli.”	ki	0.0240	uM
1-(3-imidazol-1-ylpropyl)-4-[(E)-2-phenylethenyl]indole	1165071: Inhibition of N-terminally MBP-fused human CYP24A1 by cell-free assay	ki	0.0260	uM
trans-(1R,3S,5Z)-5-[(2E)-2-[(3aS,7aS)-1-[(E,2R)-5-tert-butylsulfonylpent-4-en-2-yl]-7a-methyl-3a,5,6,7-tetrahydro-3H-inden-4-ylidene]ethylidene]-4-methylidenecyclohexane-1,3-diol	1160913: Inhibition of human MBP-tagged CYP24A1 expressed in Escherichia coli using 1,25(OH)2D3 substrate in presence of bovine adrenodoxin, adrenodoxin reductase and NADPH incubated at 37 degC for 25 mins by HPLC method	ic50	0.0270	uM
trans-(1R,3S,5Z)-5-[(2E)-2-[(3aS,7aS)-1-[(E,2R)-4-tert-butylsulfonylbut-3-en-2-yl]-7a-methyl-3a,5,6,7-tetrahydro-3H-inden-4-ylidene]ethylidene]-4-methylidenecyclohexane-1,3-diol	1704649: Inhibition of CYP24A1 (unknown origin) expressed in Chinese hamster V79 cells using [3H-1beta]-1alpha,25(OH)2D3 as substrate preincubated for 30 mins followed by substrate addition and measured after 2 hrs by scintillation counting method	ic50	0.0270	uM
trans-(1R,3S,5Z)-5-[(2E)-2-[(1R,3aS,7aR)-1-[(2R)-4-[(4-fluorophenyl)sulfonimidoyl]butan-2-yl]-7a-methyl-2,3,3a,5,6,7-hexahydro-1H-inden-4-ylidene]ethylidene]-4-methylidenecyclohexane-1,3-diol	282480: Inhibition of human CYP24 hydroxylase expressed in V79 cells	ic50	0.0280	uM
trans-(1R,3S,5Z)-5-[(2E)-2-[(1R,3aS,7aR)-1-[(2R)-4-(benzenesulfonyl)butan-2-yl]-7a-methyl-2,3,3a,5,6,7-hexahydro-1H-inden-4-ylidene]ethylidene]-4-methylidenecyclohexane-1,3-diol	1704644: Inhibition of human CYP24A1 expressed in Chinese hamster V79 cells using [3H-1beta]-1alpha,25(OH)2D3 as substrate preincubated for 10 mins followed by substrate addition and measured after 2 hrs by scintillation counting method	ic50	0.0280	uM
N-(2-imidazol-1-yl-2-phenylethyl)-4-[(E)-2-phenylethenyl]benzamide	1160913: Inhibition of human MBP-tagged CYP24A1 expressed in Escherichia coli using 1,25(OH)2D3 substrate in presence of bovine adrenodoxin, adrenodoxin reductase and NADPH incubated at 37 degC for 25 mins by HPLC method	ki	0.0280	uM
4-[(E)-2-(3,5-dimethoxyphenyl)ethenyl]-1-(3-imidazol-1-ylpropyl)indole	1165071: Inhibition of N-terminally MBP-fused human CYP24A1 by cell-free assay	ki	0.0310	uM
1-[4-[4-[[2-(2,4-dichlorophenyl)-2-(imidazol-1-ylmethyl)-1,3-dioxolan-4-yl]methoxy]phenyl]piperazin-1-yl]ethanone	1160913: Inhibition of human MBP-tagged CYP24A1 expressed in Escherichia coli using 1,25(OH)2D3 substrate in presence of bovine adrenodoxin, adrenodoxin reductase and NADPH incubated at 37 degC for 25 mins by HPLC method	ki	0.0330	uM
4-[2-(4-fluorophenyl)ethyl]-N-(2-imidazol-1-yl-2-phenylethyl)benzamide	1160913: Inhibition of human MBP-tagged CYP24A1 expressed in Escherichia coli using 1,25(OH)2D3 substrate in presence of bovine adrenodoxin, adrenodoxin reductase and NADPH incubated at 37 degC for 25 mins by HPLC method	ki	0.0360	uM
1-(3-imidazol-1-ylpropyl)-5-[(E)-2-phenylethenyl]indole	1165071: Inhibition of N-terminally MBP-fused human CYP24A1 by cell-free assay	ki	0.0370	uM
1-(4-imidazol-1-ylbutyl)-5-[(E)-2-phenylethenyl]indole	1165071: Inhibition of N-terminally MBP-fused human CYP24A1 by cell-free assay	ki	0.0370	uM
[(4R)-4-[(1R,3aS,4E,7aR)-4-[(2Z)-2-[(5S)-5-hydroxy-2-methylidenecyclohexylidene]ethylidene]-7a-methyl-2,3,3a,5,6,7-hexahydro-1H-inden-1-yl]pentyl] 4-methylbenzenesulfonate	1160913: Inhibition of human MBP-tagged CYP24A1 expressed in Escherichia coli using 1,25(OH)2D3 substrate in presence of bovine adrenodoxin, adrenodoxin reductase and NADPH incubated at 37 degC for 25 mins by HPLC method	ki	0.0390	uM
[(4S)-4-[(4E,7aR)-4-[(2Z)-2-[(5R)-5-hydroxy-2-methylidenecyclohexylidene]ethylidene]-7a-methyl-2,3,3a,5,6,7-hexahydro-1H-inden-1-yl]pentyl] 4-methylbenzenesulfonate	1799837: CYP24A1Inhibition Assay from Article 10.1021/bi101488p: “Screening of selective inhibitors of 1a,25-dihydroxyvitamin D3 24-hydroxylase using recombinant human enzyme expressed in Escherichia coli.”	ki	0.0390	uM
2-imidazol-1-yl-4,4-dimethyl-1-[4-(2-phenylethyl)phenyl]pentan-3-one	1160913: Inhibition of human MBP-tagged CYP24A1 expressed in Escherichia coli using 1,25(OH)2D3 substrate in presence of bovine adrenodoxin, adrenodoxin reductase and NADPH incubated at 37 degC for 25 mins by HPLC method	ki	0.0420	uM
cis-(1R,3S)-5-[(2E)-2-[(7aR)-1-[(2S)-5-(cyclopropylamino)pentan-2-yl]-7a-methyl-2,3,3a,5,6,7-hexahydro-1H-inden-4-ylidene]ethylidene]-2-methylidenecyclohexane-1,3-diol	1799837: CYP24A1Inhibition Assay from Article 10.1021/bi101488p: “Screening of selective inhibitors of 1a,25-dihydroxyvitamin D3 24-hydroxylase using recombinant human enzyme expressed in Escherichia coli.”	ki	0.0420	uM
trans-(1R,3R)-5-[(2E)-2-[(1R,3aS,7aR)-1-[(2R)-5-(cyclopropylamino)pentan-2-yl]-7a-methyl-2,3,3a,5,6,7-hexahydro-1H-inden-4-ylidene]ethylidene]-2-methylidenecyclohexane-1,3-diol	1160913: Inhibition of human MBP-tagged CYP24A1 expressed in Escherichia coli using 1,25(OH)2D3 substrate in presence of bovine adrenodoxin, adrenodoxin reductase and NADPH incubated at 37 degC for 25 mins by HPLC method	ki	0.0420	uM
(1S,3Z)-3-[(2E)-2-[(1R,3aS,7aR)-7a-methyl-1-[(2R)-4-(phenylsulfonimidoyl)butan-2-yl]-2,3,3a,5,6,7-hexahydro-1H-inden-4-ylidene]ethylidene]-4-methylidenecyclohexan-1-ol	282480: Inhibition of human CYP24 hydroxylase expressed in V79 cells	ic50	0.0750	uM
(4S)-4-[(4E,7aR)-4-[(2Z)-2-[(5R)-5-hydroxy-2-methylidenecyclohexylidene]ethylidene]-7a-methyl-2,3,3a,5,6,7-hexahydro-1H-inden-1-yl]pentanoic acid	1799837: CYP24A1Inhibition Assay from Article 10.1021/bi101488p: “Screening of selective inhibitors of 1a,25-dihydroxyvitamin D3 24-hydroxylase using recombinant human enzyme expressed in Escherichia coli.”	ki	0.0900	uM
N-(2-imidazol-1-yl-2-phenylethyl)-4-(phenylsulfamoyl)benzamide	1160913: Inhibition of human MBP-tagged CYP24A1 expressed in Escherichia coli using 1,25(OH)2D3 substrate in presence of bovine adrenodoxin, adrenodoxin reductase and NADPH incubated at 37 degC for 25 mins by HPLC method	ki	0.0910	uM
N-[2-imidazol-1-yl-2-(4-methoxyphenyl)ethyl]-4-[(E)-2-phenylethenyl]benzamide	1486357: Inhibition of MBP-tagged human CYP24A1 expressed Escherichia coli BL21-Gold(DE3) incubated for 25 mins in presence of Adx, AdR 1,25(OH)2D3 and NADPH by HPLC method	ic50	0.1100	uM
N-[2-(4-chlorophenyl)-2-imidazol-1-ylethyl]-4-[(E)-2-(3,4-dimethoxyphenyl)ethenyl]benzamide	1486357: Inhibition of MBP-tagged human CYP24A1 expressed Escherichia coli BL21-Gold(DE3) incubated for 25 mins in presence of Adx, AdR 1,25(OH)2D3 and NADPH by HPLC method	ic50	0.1200	uM
1-[4-[(E)-2-(3,5-dimethoxyphenyl)ethenyl]phenyl]-4,4-dimethylpentan-3-one	1160913: Inhibition of human MBP-tagged CYP24A1 expressed in Escherichia coli using 1,25(OH)2D3 substrate in presence of bovine adrenodoxin, adrenodoxin reductase and NADPH incubated at 37 degC for 25 mins by HPLC method	ki	0.1500	uM
N-[2-imidazol-1-yl-2-[4-(trifluoromethyl)phenyl]ethyl]-3-[(E)-2-phenylethenyl]benzamide	1486357: Inhibition of MBP-tagged human CYP24A1 expressed Escherichia coli BL21-Gold(DE3) incubated for 25 mins in presence of Adx, AdR 1,25(OH)2D3 and NADPH by HPLC method	ic50	0.1500	uM
N-[2-(4-chlorophenyl)-2-imidazol-1-ylethyl]-3-[(E)-2-phenylethenyl]benzamide	1486357: Inhibition of MBP-tagged human CYP24A1 expressed Escherichia coli BL21-Gold(DE3) incubated for 25 mins in presence of Adx, AdR 1,25(OH)2D3 and NADPH by HPLC method	ic50	0.1600	uM
N-[2-imidazol-1-yl-2-[4-(trifluoromethyl)phenyl]ethyl]-4-[(E)-2-phenylethenyl]benzamide	1486357: Inhibition of MBP-tagged human CYP24A1 expressed Escherichia coli BL21-Gold(DE3) incubated for 25 mins in presence of Adx, AdR 1,25(OH)2D3 and NADPH by HPLC method	ic50	0.1800	uM
N-(2-imidazol-1-yl-2-phenylethyl)-3-[(E)-2-phenylethenyl]benzamide	1486357: Inhibition of MBP-tagged human CYP24A1 expressed Escherichia coli BL21-Gold(DE3) incubated for 25 mins in presence of Adx, AdR 1,25(OH)2D3 and NADPH by HPLC method	ic50	0.1900	uM
[1-[4-[(E)-2-(3,5-dimethoxyphenyl)ethenyl]phenyl]-4,4-dimethylpentan-3-yl] 4-methylbenzenesulfonate	1160913: Inhibition of human MBP-tagged CYP24A1 expressed in Escherichia coli using 1,25(OH)2D3 substrate in presence of bovine adrenodoxin, adrenodoxin reductase and NADPH incubated at 37 degC for 25 mins by HPLC method	ki	0.2100	uM
N-[2-(4-chlorophenyl)-2-imidazol-1-ylethyl]-4-[(E)-2-phenylethenyl]benzamide	1486357: Inhibition of MBP-tagged human CYP24A1 expressed Escherichia coli BL21-Gold(DE3) incubated for 25 mins in presence of Adx, AdR 1,25(OH)2D3 and NADPH by HPLC method	ic50	0.2100	uM

CTD chemical–gene interactions

133 total (human), top 30 by PubMed support.

Chemical	Actions (top 5)	PubMed papers
Calcitriol	increases activity, decreases metabolic processing, increases abundance, decreases response to substance, affects binding (+6 more)	37
Benzo(a)pyrene	increases degradation, increases methylation, affects binding, decreases reaction, increases reaction (+2 more)	8
Lithocholic Acid	increases expression, increases reaction, decreases reaction, affects binding, increases activity	6
sodium arsenite	increases expression, affects methylation, decreases expression, affects cotreatment, increases abundance	5
Estradiol	affects cotreatment, decreases expression, increases expression	5
Valproic Acid	increases reaction, affects cotreatment, increases expression	5
lithocholic acid acetate	decreases reaction, increases expression, affects binding, increases activity, increases reaction (+1 more)	4
Calcifediol	increases expression, decreases reaction	4
Tetrachlorodibenzodioxin	increases reaction, increases expression	4
Cyclosporine	decreases expression, increases expression	4
trichostatin A	affects expression, decreases reaction, increases expression, increases reaction	3
Ketoconazole	increases expression, increases reaction, decreases activity, decreases expression, decreases metabolic processing	3
arsenite	increases methylation	2
perfluorooctanoic acid	increases expression, decreases reaction	2
seocalcitol	increases expression	2
paricalcitol	decreases expression, increases activity, affects cotreatment, increases expression	2
U 0126	increases expression, affects binding, increases reaction, decreases reaction	2
monomethylarsonous acid	decreases expression, increases methylation	2
Arsenic Trioxide	decreases reaction, increases expression, decreases expression, increases activity	2
Leflunomide	increases expression	2
Arsenic	increases abundance, increases expression, affects cotreatment, decreases expression	2
Cholecalciferol	increases expression, decreases reaction	2
Lipopolysaccharides	affects response to substance, increases expression, affects expression	2
Quercetin	decreases expression, increases expression, increases reaction	2
Rifampin	increases reaction, affects binding, increases activity, increases expression	2
Dihydrotestosterone	decreases reaction, increases expression	2
Tobacco Smoke Pollution	decreases expression, increases expression	2
Tretinoin	decreases reaction, increases expression	2
Vitamin D	decreases reaction, increases expression, affects binding, increases reaction	2
Cadmium Chloride	decreases expression, increases expression	2

ChEMBL screening assays

35 unique, capped per target: 28 binding, 7 admet

Representative assays (with source publication via chembl_document):

Assay ID	Type	Description	Source paper
CHEMBL1055571	Binding	Binding affinity to human CYP24A1 expressed in Escherichia coli assessed as catalytic efficiency after 60 mins relative 1-alpha,25-dihydroxyvitamin D3	Synthesis of 2alpha-propoxy-1alpha,25-dihydroxyvitamin D3 and comparison of its metabolism by human CYP24A1 and rat CYP24A1. — Bioorg Med Chem
CHEMBL1177226	ADMET	Inhibition of CYP24A1	Synthesis and CYP24A1 inhibitory activity of N-(2-(1H-imidazol-1-yl)-2-phenylethyl)arylamides. — Bioorg Med Chem

Cellosaurus cell lines

1 cell lines: 1 cancer cell line

First 10 cell lines (id-ordered, not curated):

Cellosaurus	Name	Category	Sex
CVCL_B2MI	Abcam A-549 CYP24A1 KO	Cancer cell line	Male

Clinical trials (associated diseases)

0 trials via MONDO — disease-level, not drug-specific.